Inhibiting inflammatory enzyme after heart attack does not reduce risk of subsequent event

31 agosto 2014

In patients who experienced an acute coronary syndrome event — such as heart attack or unstable angina — use of the drug darapladib to inhibit the enzyme lipoprotein-associated phospholipase A2 — believed to play a role in the development of atherosclerosis — did not reduce the risk of recurrent major coronary events, according to a study.